Pentagamavunon-1 (C09-1164-360)

Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 ( COX-2 ) and vascular endothelial growth factor ( VEGF ). PGV-1 inhibits NF-κB activation.In VitroPentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 µM) enhances cytotoxic effect of 5-FU on WiDr cells. Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 µM) shows different effects on cell cycle progression and induces G2/M arrest. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay. Cell Line: Human colon carcinoma WiDr. Concentration: 1, 2.5, 5, 7.5, 10, 15, and 20 µM. Incubation Time: 6, 12, 24, and 48 hours. Result: Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. Cell Cycle Analysis. Cell Line: WiDr cells. Concentration: 1, 2.5, 5, and 10 µM. Incubation Time: 24 h. Result: The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively.In VivoPentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Human cancer cells in a xenograf mouse model. Dosage: 20mg/kg. Administration: P.O. every 2 days for 20 days. Result: Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus,/nPGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells.Form:Solid. Specification: 0.99 Molecular Formula: C23H24O3 Molecular Weight: 348.43 PubChem CID: 10760152 Isomeric SMILES: CC1=CC(=CC(=C1O)C)/C=C/2/C(=O)/C(=C/C3=CC(=C(C(=C3)C)O)C)/CC2